Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
Inspire Medical Systems reported Q1 2026 revenue of $204.6 million (up 1.6% year-on-year) on 4 May 2026 and cut full-year 2026 guidance to $825-875 million from the prior $950 million-$1 billion range issued in February. The company attributed approximately $20 million of Q1 impact to CMS WISeR prior authorization and CPT code transition uncertainty. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform.
Researchers at Rockefeller University's Laboratory of Neural Systems published evidence in Nature that the ventral premotor cortex hosts the neural substrates of abstract symbolic thought, identifying a brain region that mediates between the higher-thinking prefrontal cortex and the action-executing motor cortex. The finding has direct implications for BCI decoding targets: implants placed at the ventral premotor cortex could potentially decode user intent at a higher level of abstraction than current motor-cortex BCIs.
Synchron co-founder and CEO Tom Oxley publicly criticised Treasurer Jim Chalmers's proposed capital gains tax changes in The Australian on 25 May 2026, joining a growing Australian founder coalition arguing the 2026-27 federal budget reforms would push tech talent and startup equity offshore. The Chalmers budget, handed down 12 May 2026, proposes removing the 50% CGT discount from 1 July 2027 and replacing it with cost-based indexation plus a 30% minimum tax on net capital gains.
The Friday $7.5 million seed round for Neurosoft Bioelectronics is the latest commercial output from a Lausanne-Geneva neurotechnology cluster anchored on EPFL's Neuro-X Institute at Campus Biotech Geneva. The same cluster has produced ONWARD Medical (now NASDAQ-listed brain-spine interface company), MindMaze (Lausanne-founded brain-technology unicorn), and the academic research that China's brain-spine clinical programmes are now structurally copying.
A paraplegic patient who in May 2025 became the world's first to simultaneously receive the invasive Beinao No.1 brain-computer interface and a temporally programmed spinal cord stimulation system has improved from complete to incomplete spinal cord injury (ASIA Grade A to ASIA Grade C) after one year of staged rehabilitation, the Xuanwu Hospital Capital Medical University team disclosed on 22 May 2026.
NIH BRAIN Initiative Director John Ngai and Acting NINDS Director Amy Bany Adams jointly announced the formal publication of the BRAIN Initiative's 10-year Neuroscience Research Roadmap on 15 May 2026, with a Director's Message and a paper in Neuron. The roadmap, finalised in August 2025, organises the next decade of US federally-funded neuroscience around four Innovation Domains: BRAIN Knowledgebase, Precision Molecular Circuit Therapies, Accelerating Human Neuroscience, and BRAIN NeuroAI.
Neuralink disclosed on 7 May 2026 that its next-generation R1 surgical robot can place electrode threads into virtually any region of the human brain, threading through the dura mater with real-time motion compensation and a suite of eight optical coherence tomography cameras. The scope expansion opens Parkinson's disease, refractory epilepsy, and treatment-resistant depression as new target indications beyond motor-function restoration.
Neurosoft Bioelectronics closed a $7.5 million oversubscribed seed round on 20 May 2026, led by Skybound Venture Capital and joined by PL Capital, IAG Capital Partners, and Connecticut Innovations. The round brings Neurosoft's total funding past $20 million and is the inaugural investment from Skybound, a new Athens-based deeptech fund publicly launched the same week with a $38 million first close anchored by the European Investment Fund.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.